Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 2/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | HTR2C | P28335 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | DPP4 | P27487 | 1/20 | 0.34 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.34 |
| ▸ | PREP | P48147 | 1/20 | 0.34 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4747822 | 0.89 | TP53 (0.39) | MCHR1TP53HTR2CHTTDPP4 | |
| SCHEMBL14033586 | 0.85 | HTT (0.35) | TP53HTTALDH1A1 | |
| SCHEMBL4747039 | 0.85 | MEN1 (0.38) | TP53HTTALDH1A1 | |
| SCHEMBL5124478 | 0.82 | GRM2 (0.35) | DPP4DPP8 | |
| SCHEMBL4746413 | 0.81 | CYP2D6 (0.38) | TP53HTTALDH1A1 | |
| SCHEMBL4750169 | 0.81 | TP53 (0.36) | TP53ALDH1A1SMN1; SMN2 | |
| SCHEMBL14034169 | 0.76 | GRM2 (0.35) | — | |
| SCHEMBL5112048 | 0.75 | MEN1 (0.41) | TP53HTTALDH1A1 | |
| SCHEMBL4752558 | 0.75 | KCNH2 (0.36) | MCHR1TP53HTT | |
| SCHEMBL4744312 | 0.74 | KCNH2 (0.41) | HTTALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7435735-B2 | Hydroxy pyridopyrrolopyrazine dione compounds useful as HIV integrase inhibitors | MERCK & CO., INC. (US) | 2008-10-14 | — | — | US | claimed |
| US-20070093496-A1 | Hydroxy pyridopyrrolopyrazine dione compounds useful as hiv integrase inhibitors | MERCK SHARP & DOHME CORP. | 2007-04-26 | — | — | US | claimed |
| US-7435735-B2 | Hydroxy pyridopyrrolopyrazine dione compounds useful as HIV integrase inhibitors | MERCK & CO., INC. (US) | 2008-10-14 | — | — | US | disclosed |
| US-7435735-B2 | Hydroxy pyridopyrrolopyrazine dione compounds useful as HIV integrase inhibitors | MERCK & CO., INC. (US) | 2008-10-14 | — | — | US | disclosed |
| US-7435735-B2 | Hydroxy pyridopyrrolopyrazine dione compounds useful as HIV integrase inhibitors | MERCK & CO., INC. (US) | 2008-10-14 | — | — | US | disclosed |
| US-20070093496-A1 | Hydroxy pyridopyrrolopyrazine dione compounds useful as hiv integrase inhibitors | MERCK SHARP & DOHME CORP. | 2007-04-26 | — | — | US | disclosed |
| US-20070093496-A1 | Hydroxy pyridopyrrolopyrazine dione compounds useful as hiv integrase inhibitors | MERCK SHARP & DOHME CORP. | 2007-04-26 | — | — | US | disclosed |
| US-20070093496-A1 | Hydroxy pyridopyrrolopyrazine dione compounds useful as hiv integrase inhibitors | MERCK SHARP & DOHME CORP. | 2007-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070093496-A1 | Hydroxy pyridopyrrolopyrazine dione compounds useful as hiv integrase inhibitors | DHPS, DPYD, TYMP | MCHR1 2366/4885TP53 645/4885HTR2C 2981/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.